Regular Articles
Estrogen Receptor α Controls a Gene Network in Luminal-Like Breast Cancer Cells Comprising Multiple Transcription Factors and MicroRNAs

https://doi.org/10.2353/ajpath.2010.090837Get rights and content
Under an Elsevier user license
open archive

Luminal-like breast tumor cells express estrogen receptor α (ERα), a member of the nuclear receptor family of ligand-activated transcription factors that controls their proliferation, survival, and functional status. To identify the molecular determinants of this hormone-responsive tumor phenotype, a comprehensive genome-wide analysis was performed in estrogen stimulated MCF-7 and ZR-75.1 cells by integrating time-course mRNA expression profiling with global mapping of genomic ERα binding sites by chromatin immunoprecipitation coupled to massively parallel sequencing, microRNA expression profiling, and in silico analysis of transcription units and receptor binding regions identified. All 1270 genes that were found to respond to 17β-estradiol in both cell lines cluster in 33 highly concordant groups, each of which showed defined kinetics of RNA changes. This hormone-responsive gene set includes several direct targets of ERα and is organized in a gene regulation cascade, stemming from ligand-activated receptor and reaching a large number of downstream targets via AP-2γ, B-cell activating transcription factor, E2F1 and 2, E74-like factor 3, GTF2IRD1, hairy and enhancer of split homologue-1, MYB, SMAD3, RARα, and RXRα transcription factors. MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17β-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.

Cited by (0)

Supported by UE (CRESCENDO IP, contract n.er LSHM-CT2005-018652); Italian Association for Cancer Research, (grant IG-8586) Region Campania (L. 5 and POR); Ministry of Education, University and Research (grant 2008 CJ4 SYW_004, to A.W.); DISSPAPA (to M.L.C.); Region Piedmont (PRF Health 2006, 2007, and Applied Science 2004); Ministry of Health (PRF 2005, to M.D.B.); and the Ph.D. programs: Pathology of Cell Signal Transduction (O.P., O.M.V.G., and R.T.), Computational Biology (A.T.) of the Second University of Naples, and Toxicology, Oncology, and Molecular Pathology of the University of Cagliari (M.R.). M.M. is a recipient of a postdoctoral fellowship of the Second University of Naples, and O.P. is a recipient of a Doctoral Fellowship from the AIRC Naples Oncogenomics Center.

Supplemental material for this article can be found on http://ajp.amjpathol.org.